Tiziana Life Sciences PLC- London-based therapeutics for oncology, inflammation and infectious diseases - Files a universal shelf registration statement on form F-3 with the US Securities & Exchange Commission in relation to up to USD250.0 million in market value of its securities. This kind of filing is common among NASDAQ-listed companies and allows issues to have quicker and more efficient access to US capital markets.
Tizianas's registration statement also include a preliminary prospectus supplement related an "at-the-market" sales agreement which the firm plans to enter into with B Riles Securities Inc. Under this agreement, Tiziana may sell up to USD100.0 million of securities registered under the registration statement in market value off American depositary shares through B Riley. Tiziana has no immediate plans to offer or sell securities under the registration statement or this at-the-market programme.
"The specifics of any future offering pursuant to the registration statement, such as the prices and terms of the securities offered, will be determined at the time of any such offering and will be described in detail in a prospectus supplement filed by the company with the SEC in connection with such offering," says Tiziana.
Current stock price: 161.36 pence
Year-to-date change: up 76%
By Anna Farley; annafarley@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
